Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GCG | P01275 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717719 | 0.98 | TP53 (0.36) | GCGRTP53MAPTRXFP1L3MBTL1 | |
| SCHEMBL718454 | 0.94 | GCGR (0.38) | GCGRGCGHDAC6NAMPT | |
| SCHEMBL719013 | 0.93 | GCGR (0.37) | GCGRGCGHDAC6NAMPT | |
| SCHEMBL721279 | 0.89 | NAMPT (0.33) | MAPTL3MBTL1TSHRMEN1KMT2A | |
| SCHEMBL722172 | 0.88 | RCE1 (0.41) | MAPTL3MBTL1TSHRLMNAMEN1 | |
| SCHEMBL721611 | 0.87 | RCE1 (0.37) | MAPTL3MBTL1TSHRMEN1GAA | |
| SCHEMBL717506 | 0.86 | MEN1 (0.36) | TP53MAPTRXFP1L3MBTL1TSHR | |
| SCHEMBL718563 | 0.86 | NAMPT (0.34) | MAPTL3MBTL1MEN1GAAKMT2A | |
| SCHEMBL3401014 | 0.86 | NAMPT (0.34) | MAPTL3MBTL1MEN1GAAKMT2A | |
| SCHEMBL719238 | 0.85 | RCE1 (0.41) | MAPTL3MBTL1TSHRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885TP53 293/4885MAPT 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.